2. Search Result
Search Result
Results for "

solid tumours

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

6

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99450
    Avdoralimab

    IPH 5401; Anti-C5aR1 mAb

    		 Complement System Inflammation/Immunology Cancer
    Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
    Avdoralimab
  • HY-111786
    LHC-165

    		Toll-like Receptor (TLR) Cancer
    LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .
    LHC-165
  • HY-P99157
    Omburtamab

    		CD276/B7-H3 Cancer
    Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research .
    Omburtamab
  • HY-P99114
    Sugemalimab

    		PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
    Sugemalimab
  • HY-P99011
    Cibisatamab

    		CD3 Cancer
    Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .
    Cibisatamab
  • HY-139453A
    LP-284

    		DNA Alkylator/Crosslinker Cancer
    LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .
    LP-284
  • HY-16215
    Mipsagargin

    G-202

    		 Drug-Linker Conjugates for ADC Cancer
    Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .
    Mipsagargin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: